Zalcitabine 2-3 -dideoxycytidine, ddc TUD DaMocles SoSe 15
|
|
- Melvyn Atkinson
- 5 years ago
- Views:
Transcription
1 Zalcitabine 2-3 -dideoxycytidine, ddc TUD DaMocles SoSe 15 Nina Drechsler, Christoph Drexler, Robin Dursun, Malte Eckert Graphic 1: Zalcitabine
2 Table of Contents Content Introduction Properties Physical Properties Safety Information Structure Synthesis History Medical Information NRTIs used to treat HIV About Zalcitabine Biological Effects HIV Treatments Sources 8
3 1. Introduction Graphic 2: Zalcitabine. Zalcitabine is a nucleoside analogue reverse transcriptase inhibitor (short: NRTI), which was first synthesized by Jerome Horwitz in , and was used to treat human immunodeficiency virus (HIV) from 1992 until Reverse transcriptase inhibitors prevent the reproduction of HIV by interrupting the process of polymerase. 2. Properties 2.1. Physical Properties Molecular Formula C9H13N3O3 Molecular Weight 211,22 g/mol Melting Point 217 C Zalcitabine is a color- and odorless powder, soluble in water (~80g/L) and DMSO (~100g/L) and only stable for 90 days at room temperature Safety Information Warning Hazard Statements 4 H351 Suspected of causing cancer. H361 Suspected of damaging fertility or the unborn child. Precautionary Statements 5 P281 Use personal protective equipment as required.
4 3. Structure Graphic 3: Structure of Zalcitabine. Graphic 4: Structure of Cytidine. Zalcitabine is an analog of the nucleoside cytidine. The difference is the missing 3 OH-group located on the ribose molecule. Nucleosides consist of a nucleobase and a ribose. Graphic 5: composition of nucleosides (black) and nucleotides (colored). Graphic 6: Desoxyribose. Graphic 7: Cytosine, one out of four nucleobases relevant to the DNA/ RNA. The other three being Adenine, Guanine and Thymine.
5 4. Synthesis Graphic 8: synthesis of Zalcitabine in 6 steps. Source of synthesis: Motawia, Mohammed S.; Pedersen, Erik B., Liebigs Annalen der Chemie Issue 6 Pages Journal 1990 The shown synthesis consists of six steps including the most important ones: Ring closure of 2-deoxy-D-erythro-pentose Substituting the OH-group in position 4 with an H Substituting MeO in position 5 with a propanamide.
6 5. History Zalcitabine was first synthesized in 1966 by Jerome Howitz, Detroit Institute of Cancer Research, Michigan, USA. It was first approved by the Food and Drug Administration (USA) on June 19 th, Zalcitabine, sold as monotherapy medicine named HIVID by Hofmann-LaRoche, was the third antiretroviral released, while Zidovudine was available as Retrovir by GlaxoSmithKline since 1987 and Didanosine was marketed as Videx by Bristol-Myers Squibb since Starting in 1996 Zalcitabine was used combined with Zidovudine to improve effectivity/ lower the progress of the disease even further. 7 In 1997 Zalcitabine was combined with Saquinavir (protease inhibitor, PI) due the combined therapy leading to higher PHS (physical health summary) and MHS (mental health summary) scores. 8 In 2006 Zalcitabine was discontinued by Hofmann-LaRoche and replaced with newer NRTI/PI combinations Medical Information 6.1. NRTIs used to treat HIV Active Ingredient Producer, Drug Approval Emtricitabine, FTC Gilead Sciences, Emtriva Limivudine, 3TC GlaxoSmithKline, Epivir Zidovudine, ZDV Glaxosmithkline, Retrovir enteric coated didanosine, ddi EC Bristol Myers-Squibb, Videx EC dideoxyinosine, ddi Bristol Myers-Squibb, Videx tenofovir disoproxil fumarate, TDF Gilead, Viread stavudine, d4t Bristol Myers-Squibb, Zerit abacavir sulfate, ABC GlaxoSmithKline, Ziagen Apricitabine Avexa Pharmaceuticals in development Table 1: NRTIs used to treat HIV
7 6.2. About Zalcitabine Zalcitabine was indicated as monotherapy if the patient had been intolerant of alternative antiretroviral therapy. It was used in combination with protease inhibitors (PI) if the patient has been treated with other NRTI (e. g. Zidovudine) prior to Zalcitabine. A positive trait of Zalcitabine is it s high oral bioavailability (above 80%) and the short time needed to absorb it (approximately hours). Due to its very short half life time (1-3 hours) it has to be taken in three times per day. 12 The intolerance rate of Zalcitabine is lower than that of other NTRIs but the adverse events range from nausea and headaches to peripheral neuropathy, pancreatitis, oral and oesophageal ulcers. 13 These side effects are common among NRTIs and based on their toxic effect on mitochondria because the NRTI-triphosphates are intervening in the process of mitochondrial reproduction. This leads to decreased mitochondrial energy-generating capacity, constraining the respiratory chain and citric acid cycle and a disequilibrium in energy balance. 7. Biological Effects 7.1. HIV The human immunodeficiency virus (HIV) infects vital parts of the immune system, preferably CD4 + T-cells, in order to replicate itself. 14 The loss of T-cells due to infected cells not functioning as planned and the destruction of infected cells weakens the immune system of the patient which will eventually lead to the death of the host. 15 Graphic 9: Schematic representation of the human immunodeficiency virus. On the outside: glycoproteins of the membrane. Inside: RNA-genome (red) reverse transcriptase enzymes (blue). Source: Stryer,Lubert: Biochemie. 4.Auflage. Spektrum Akademischer Verlag, Heidelberg; Berlin; Oxford, 1996, S. 404.
8 Graphic 10: The cycle of reproduction of HIV. It infects T-cells, programs them to replicate the virus via reverse transcriptase and lead to the death of the infected cell after finishing reproducing. Source: Biologie Oberstufe. Gesamtband. Cornelsen, Berlin: 2001, S HIV has three essential enzymes which are needed to replicate the virus: 1. Reverse transcriptase: a viral RNA/DNA-polymerase changes the viral RNA into a proviral DNA 2. Integrase: integration of the proviral DNA into the DNA of the host cell. Viral polyprotein complexes develop 3. HIV-protease: final stage of reproduction, polyprotein complexes split into singular proteins. The new viruses are able to infect other T-cells Graphic 11: Life cycle of retroviruses. Source: Stryer, Lubert: Biochemie. 4.Auflage. Spektrum Akademischer Verlag, Heidelberg; Berlin; Oxford, 1996, S. 95.
9 7.2. Treatments If left untreated, HIV leaves the person with a life expectancy of 9-11 years. In the final stage of the disease, which is called acquired immunodeficiency syndrome (AIDS), the human body has almost no working immune system left and is susceptible to life-threatening diseases. Zalcitabine and other NRTIs or PIs are not able to eliminate HIV, but these medications lead to a higher life expectancy and better health conditions for the patients by halting the spread of the virus. Nowadays the combined antiretroviral therapy (cart) is used to treat HIV. As the name implies, it uses a combination of different types of medication: 1. NRTI: nucleoside analogue reverse transcriptase inhibitors 2. NNRTI: non-nucleoside reverse-transcriptase inhibitors 3. PI: protease inhibitors 4. FI: entry-inhibitors (or fusion inhibitors) 5. INSTI: integrase strand transfer inhibitors. Zalcitabine belongs to the category of NRTIs. It is a derivate of deoxycytidine. When reaching the target cell, it is activated by being phosphorylated and turned into the active triphosphate (ddcpt). This triphosphate competes as alternate substrate in reverse transcriptase of HIV. When Zalcitabine is used in the transcription process it terminates the process of reproduction, due to missing a 3 -OH-group, which is needed in the next step to build a phosphor-di-ester bond. Without these bonds the replication process will not be able to produce a steady DNA. 16 Graphics 12.1 and 12.2: Comparison of a successful phosphor-di-ester bond to a missing bond. Graphic 13: Guanine (black) and cytidine (red) as part of the RNA.
10 8. Sources 1 J. Horwitz, J. Org. Chem, 32 (1), 1967, abgerufen am abgerufen am abgerufen am abgerufen am E. De Clercq, International Journal of Antimicrobial Agents, 33 (2009), C. Craig, G. Moyle, AIDS, 11, 1997, D. Revicki, Antiviral Therapy, 4, 1999, abgerufen P. Cahn, AIDS, 20 (9), 2006, abgerufen am Instruction leaflet: abgerufen Biologie Oberstufe. Gesamtband. Cornelsen, Berlin: Garg H, Mohl J, Joshi A (Nov 9, 2012). HIV-1 induced bystander apoptosis 16
HIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationHIV - Life cycle. HIV Life Cyle
Human Immunodeficiency Virus Retrovirus - integrated into host genome ne single-strand RA 7,000 bases HIV1 > HIV2 > HIV0 Pathology Destruction of CD4+ T lymphocytes Loss of immune function pportunistic
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationTreatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if
More informationUnderstanding Viruses CHAPTER 38. Antiviral Agents. Understanding Viruses (cont'd) Viral Infections (cont'd) Viral Infections.
Understanding Viruses CHAPTER 38 Antiviral Agents Viral replication A virus cannot replicate on its own It must attach to and enter a host cell It then uses the host cell s energy to synthesize protein,
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationAntiviral Agents DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU. 06 August
Antiviral Agents Dr. Yunita Sari Pane, MS DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU 06 August 2009 1 VIRUSES Obligate intracellular parasites Consist of a core genome in a protein shell and some are surrounded
More informationMedChem 401~ Retroviridae. Retroviridae
MedChem 401~ Retroviridae Retroviruses plus-sense RNA genome (!8-10 kb) protein capsid lipid envelop envelope glycoproteins reverse transcriptase enzyme integrase enzyme protease enzyme Retroviridae The
More informationMedscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationAntiviral Chemotherapy
Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
More informationHIV epidemiology since HIV in the United States. HIV Transmission
HIV epidemiology since 1999 8% increase in HIV diagnoses Men who have sex with men (MSM) increased 14% Heterosexual increased 10% IVDU decrease about 30% Young Black MSM 15% incidence HIV in the United
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More informationC h a p t e r 5 5 HIV Therapy Where are We Now?
C h a p t e r 5 5 HIV Therapy Where are We Now? AK Tripathi Professor of Medicine, Physician & Haemato-Oncologist, King George s Medical College, Lucknow Introduction Human Immunodeficiency Virus type
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationWOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationPage 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
More informationAntiviral Drugs Lecture 5
Antiviral Drugs Lecture 5 Antimicrobial Chemotherapy (MLAB 366) 1 Dr. Mohamed A. El-Sakhawy 2 Introduction Viruses are microscopic organisms that can infect all living cells. They are parasitic and multiply
More informationQuick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents
Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationTreatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) modified by Diala Abul Haija
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) modified by Diala Abul Haija Amantadine and Rimantadine very limited capabilities reduces symptoms Use is limited
More informationAntiviral Agents I. Tutorial 6
Antiviral Agents I Tutorial 6 Viruses, the smallest of pathogens, are unable to conduct metabolic processes on their own, they use the metabolic system of the infected cell to replicate ( intracellular
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationHands-on Activity Viral DNA Integration. Educator Materials
OVERVIEW This activity is part of a series of activities and demonstrations focusing on various aspects of the human immunodeficiency virus (HIV) life cycle. HIV is a retrovirus. Retroviruses are distinguished
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationHIV and AIDS. Shan Nanji
HIV and AIDS Shan Nanji HIV 2 Description: Enveloped Positive Sense HIV 3 Structural Genes: Cleavage of gp160 leads to formation of ENV: Gp120: attachment to host CD4 T Cell Gp41: GAG (p24) Capsid protein
More informationDTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone
DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone Aboud M, 1 Brites C, 2 Lu H, 3 Supparatpinyo K, 4 Hercilla L, 5 Sievers J, 1 Nascimento MC, 1 Hopking J, 6 Underwood
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationHIV long term complications
HIV- 2015 long term complications 4th Asian Conference on Hepatitis & AIDS 22-23 May 2015, Xi'an, China Kees Brinkman Amsterdam The Netherlands NL 2012: known 17.000 (0,1%) treatment 85% (all) China 2011:
More informationRE: NDA # Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets MACMIS # 18360
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Joyce Q. Acbay Director, Regulatory Affairs 333 Lakeside Drive
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationMedication Guide. VIDEX EC (VY-dex Ee-see) (didanosine, also known as ddi) Delayed-Release Capsules Enteric-Coated Beadlets
Medication Guide VIDEX EC (VY-dex Ee-see) (didanosine, also known as ddi) Delayed-Release Capsules Enteric-Coated Beadlets Read this Medication Guide before you start taking VIDEX EC and each time you
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
More informationCLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:
CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer
More informationFuzeon A Review of the First Entry Inhibitor By Cal Cohen, M.D., M.S.
Fuzeon A Review of the First Entry Inhibitor By Cal Cohen, M.D., M.S. Table of Contents Introduction: Why Do We Need a New Class of HIV Medications?... 3 Entry Inhibitors: A New Class of HIV Medications...
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 EDURANT 25 mg film-coated tablets B/30 (CIP code: 219 472-9) Applicant: JANSSEN-CILAG rilpivirine ATC code
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationIndustry Request Integrase Inhibitors
Industry Request Integrase Inhibitors The objective of this request is to describe and understand the temporal changes in the prescribing practices of Integrese Inibitors (II) in AHOD cohort between 1/1/
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationOctober 26, Lecture Readings. Vesicular Trafficking, Secretory Pathway, HIV Assembly and Exit from Cell
October 26, 2006 Vesicular Trafficking, Secretory Pathway, HIV Assembly and Exit from Cell 1. Secretory pathway a. Formation of coated vesicles b. SNAREs and vesicle targeting 2. Membrane fusion a. SNAREs
More informationCHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
More informationd4t (stavudine, Zerit)
d4t (stavudine, Zerit) Summary d4t (stavudine, Zerit) is a type of anti-hiv drug called a nuke or nucleoside analogue. Common side effects of d4t can include headache, nausea, vomiting and diarrhea. d4t
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationAntiretrovial Crushable/Liquid Formulation Chart
Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in
More informationACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS
ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS Acquired immunodeficiency syndrome (AIDS ) is an infectious disease caused by a retrovirus, the human immunodeficiency virus(hiv). AIDS is
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationA Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More information19 Viruses BIOLOGY. Outline. Structural Features and Characteristics. The Good the Bad and the Ugly. Structural Features and Characteristics
9 Viruses CAMPBELL BIOLOGY TENTH EDITION Reece Urry Cain Wasserman Minorsky Jackson Outline I. Viruses A. Structure of viruses B. Common Characteristics of Viruses C. Viral replication D. HIV Lecture Presentation
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Enfuvirtide (Fuzeon) Reference Number: CP.PHAR.41 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationAntiretroviral Pregnancy Registry
Preterm Birth, low birth weight and fetal antiretroviral exposure: Estimated gestational age and birth weight data from singleton live births, 1989 through 31 January 2009 K. Beckerman, J. Albano, M. Martinez-Tristani,
More informationGenotyping and Drug Resistance in Clinical Practice. Case Studies
Genotyping and Drug Resistance in Clinical Practice Case Studies 12/02 40 year old Hispanic male Dx with HIV 1995 + Hx of PCP > 1x, HepC Medication history: AZT, Crixivan, Videx EC, Sustiva, Zerit, Ziagen,
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationResistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine
Journal of Antimicrobial Chemotherapy Advance Access published December 9, 2009 J Antimicrob Chemother doi:10.1093/jac/dkp422 esistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine
More informationHydroxyurea with ddi or ddi/d4t: a novel approach to HIV therapy
National AIDS Treatment Advocacy Project Hydroxyurea with ddi or ddi/d4t: a novel approach to HIV therapy Results from several hydroxyurea (ddi+hydroxyurea) studies were reported at Vancouver (July `96)
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationTenofovir Disoproxil Emtricitabine Mylan 300/200 Tenofovir disoproxil maleate 300 mg and Emtricitabine 200 mg
Tenofovir Disoproxil Emtricitabine Mylan 300/200 Tenofovir disoproxil maleate 300 mg and Emtricitabine 200 mg PRODUCT INFORMATION NAME OF THE MEDICINE The active substances in Tenofovir Disoproxil Emtricitabine
More informationBecause accurate and reproducible phenotypic susceptibility
BRIEF REPORT: CLINICAL SCIENCE Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays Jie Zhang, MS,* Soo-Yon Rhee, MS,* Jonathan Taylor, PhD, and
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationAnti-viral drugs. Certain viruses multiply in the cytoplasm but others do in the nucleus Most multiplication take place before diagnosis is made
Anti-viral Drugs Viruses have no cell wall and made up of nucleic acid components Viruses containing envelope antigenic in nature Viruses are obligate intracellular parasite They do not have a metabolic
More informationOctober 26-28: Training Day 1
Peer Linkage and Re-Engagement of HIV- Positive Women of Color October 26-28: Training Day 1 Peer Linkage and Re -Engagement of HIV - Positive Women of Color Convening Training Trainers Today: Alicia Downes
More informationHow HIV Works in Your Body
How HIV Works in Your Body It helps to know what s going on with your virus What is HIV and how do people get it? The initials HIV stand for Human Immunodeficiency Virus meaning a virus that causes the
More informationHIV Infection & AIDS in Low- and Middle-Income Countries
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationHIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time
STRATEGIES FOR FIRST LINE HIV THERAPY issues to think about when going on therapy for the first time A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Deciding
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationRapid Review Response HIV Medication and Depression
Rapid Review Response HIV Medication and Depression Question: Is depression a side effect of anti-retroviral medications taken by people living with HIV? The issue and why it s important The Ontario HIV
More informationHIV AND ANTIRETROVIRALS: A DISPENSERS PERSPECTIVE WITH A FOCUS ON DRUG INTERACTIONS DR. M.M. PEZA MBCHB (UCT) PG DIPLOMA (HEALTH ECONOMICS) (UCT)
HIV AND ANTIRETROVIRALS: A DISPENSERS PERSPECTIVE WITH A FOCUS ON DRUG INTERACTIONS DR. M.M. PEZA MBCHB (UCT) PG DIPLOMA (HEALTH ECONOMICS) (UCT) 2/21/2014 HIV STATISTICS IN SOUTH AFRICA One in every 10
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationChapter 49. Antiviral Agents
Chapter 49 Antiviral Agents Antiviral Drugs 1. Characters of Virus Viruses are obligate intracellular parasites their replication depends primarily on synthetic processes of the host cell. 2.Classification
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationThe head of a pin can hold five hundred million rhinoviruses (cause of the
The head of a pin can hold five hundred million rhinoviruses (cause of the common cold). One sneeze can generate an aerosol of enough cold viruses to infect thousands of people! DNA-containing Viruses:
More informationDifferentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail
HAART, HIV correlated pathologies and other infections Renato Maserati Differentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail Corresponding
More informationAntivirals. Lecture 20 Biology 3310/4310 Virology Spring 2017
Antivirals Lecture 20 Biology 3310/4310 Virology Spring 2017 You can t go back and you can t stand still. If the thunder don t get you, then the lightning will. JERRY GARCIA The Wheel (lyrics by Robert
More informationSection 6. Junaid Malek, M.D.
Section 6 Junaid Malek, M.D. The Golgi and gp160 gp160 transported from ER to the Golgi in coated vesicles These coated vesicles fuse to the cis portion of the Golgi and deposit their cargo in the cisternae
More informationVIREAD Tablets 300 mg tenofovir disoproxil fumarate
VIREAD Tablets 300 mg tenofovir disoproxil fumarate Consumer Medicine Information What is in this leaflet Read this leaflet carefully before you start taking VIREAD. Also, read it each time you get your
More informationAntiviral Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
Antiviral Drugs Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Viruses Viruses are the smallest infective agents, consisting of nucleic acid (DNA or RNA) enclosed
More informationLESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV
LESSON 4.6 WORKBOOK Designing an antiviral drug The challenge of HIV In the last two lessons we discussed the how the viral life cycle causes host cell damage. But is there anything we can do to prevent
More informationHIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs),
More informationThe Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease
The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project ARV Dosing in End Stage Renal Disease 1. Jayasekara, D., Aweeka, F. T., Rodriguez, R., Kalayjian, R. C., Humphreys, M. H.,
More information